Chart Advisor: One of the market’s most hated groups just stirred

Investopedia is partnering with All Star Charts on this newsletter.  The contents of this newsletter are for informational and educational purposes only.

One of the market’s most hated groups just stirred

One of the most hated corners of the market just made a noise loud enough to turn heads.

Biotech has been a graveyard for years. While the crowd piled into AI and the megacaps, the small and mid-sized drug names sat in a drawer collecting dust, and AbCellera sat there with them. 

The stock came public valued north of $15 billion and spent the next few years bleeding down toward $1 billion. Almost nobody was still watching.

Then it jumped nearly 30% in a single week, on the heaviest volume it has ever traded, and closed last Friday at 7.38 at a fresh 52-week high. That is exactly why this chart is worth a look right now.

Pull up the weekly and you see why. AbCellera (ABCL) has spent since 2023 carving a long, rounded bottom, the slow saucer-shaped base that takes years to build. 

Last week price pushed up through the top of that structure for the first time in a way that counts.

Here is the honest catch, and it sits right on the chart. One hot week does not confirm a base that took more than two years to form. A skeptic has every reason to call this another bounce in a stock that has faked out before, and they would not be crazy. The real question the chart is asking is whether this breakout holds, or slips back into the base like the others did.

What tilts the odds is not happening on AbCellera’s chart at all. It is happening one level up, in the group.

The high-beta biotech ETF, XBI, has been breaking out. When that fund leads, it means risk appetite is expanding, and the speculative money tends to flood straight into the beaten-down individual names. That is the exact tape where left-for-dead biotechs put in major bottoms and re-rate fast. 

AbCellera is not moving in a vacuum. It is moving because the whole group finally turned.

Under the surface, the smart money was already there. Baker Bros. Advisors, among the most respected biotech investors alive, held about 33 million AbCellera shares as of April, near 11% of the company. When money that informed sits that heavy in a name the market gave up on, it tells you the conviction was there long before the chart moved.

The takeaway is not to chase it. 

It is that a stock almost nobody was watching just cleared a line that took years to build, with the group catching fire behind it and serious money already inside. How it behaves at this line over the coming weeks will tell you most of what you need to know.

The hard part, as always, is telling the breakouts that hold from the ones that trap you.

That is the work we do every day at the 2-to-100 Club, reading which groups are turning and where the next move sets up before the names make the news.

—

Originally posted 29th June 2026